IDH1/2 Mutation Detection Kit

More Views

The key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair are Isocitrate dehydrogenase 1 and 2 (IDH1/2). Mutations in IDH1/2 can lead to the evolution and/or progression of various types of cancer such as secondary glioblastomas and acute myeloid leukaemias (AML). IDH1/2 mutations are linked to abnormal histone and DNA methylation which may generate altered stem cell differentiation and eventual tumorigenesis. The unique features of IDH1/2 mutations make them good biomarkers and promising medication targets.

Add to Shortlist

Features & Benefits

Low input requirement
Easy setup & interpretation

Product Details

Glioblastoma:

Proof shows that IDH mutations are firmly connected with MGMT promoter methylation. MGMT promoter methylation prompts expanded sensitivity to alkylating agents, such as temozolomide, and has prognostic importance like IDH mutations. IDH1/2 mutations are prognostic in GBM and are related to a better outcome than IDH1/2-negative GBM.

Acute Myeloid Leukemia (AML):

IDH1/2 mutations are found in around 20% of AML patients. Mutations in the IDH1/2 genes are known to disrupt several cell processes which eventually stops bone marrow cells from maturing properly. IDH inhibitors are designed to support leukaemia cells mature into normal blood cells. Some of these drugs, such as enasidenib (Idhifa) and ivosidenib (Tibsovo), are now approved to treat AML with certain IDH gene mutations.
IDH 1/2 assay is 38 reactions which is polymerase chain reaction (PCR)-based that detects somatic mutations in DNA isolated from blood or tissue in three multiplexed reactions. It performs by amplifying mutant-specific sequences in DNA samples.
EntroGen’s IDH1/2 assay requires a real-time PCR instrument capable of detecting FAM and VIC fluorescent probes.